

### Agenda

<b>Saturday, April 30</b>		
<b>4:00-5:00 PM</b>	<b>ITOG/ACCRU Meeting</b>	ACCRU Team, Executive Committee, Protocol Sub-Committee Chairs
<b>5:00-6:00 PM</b>	<b>Committee Meetings</b>	Protocol, Membership, Finance, Correlative Sciences, Bylaws
<b>6:00-9:00 PM</b>	<b>Board Meeting (w/ working dinner)</b>	ITOG Board
<b>Sunday, May 1</b>		
<b>6:45-7:30 AM</b>	<b>Breakfast</b>	
<b>7:20-7:30 AM</b>	<b>Welcome</b>	Bryan Haugen and Rebecca Schweppe
<b>7:30-9:45 AM</b>	<b>Session I – Tumor Immunology</b>	Nighhorse Campbell Building Shore Family Conference Room
7:30-8:00 AM	Investigating the Potential for PD-1/PD-L1 Blockades in Advanced Thyroid Cancer	Jena French
8:00-8:30 AM	Approaches to targeting TAMs in advanced thyroid cancers	Mabel Ryder
8:30-9:00 AM	Thyroid cohort extension trial of Ipilimumab and Hypofractionated Stereotactic Radiation Therapy	Ramona Dadu
9:00-9:30 AM	T-Cells as Cancer Therapy: Thyroid Cancer and Beyond	James Yang
9:30-9:45 AM	<i>ITOG trials update:</i> Lenvatinib + Pembrolizumab in DTC	Bryan Haugen
<b>9:45-10:15 AM</b>	<b>Break</b>	
<b>10:15 - 12:30 PM</b>	<b>Session II – Kinase signaling</b>	
10:15-10:45 AM	Targeting RET and ATF4 pathway to induce apoptosis in MTC	Rozita Yarmand
10:45-11:05 AM	Targeting RET in Thyroid and Lung Cancer	Erica Evans ( <i>Blueprint Pharm</i> )
11:05-11:25 AM	Targeting addicting kinases in thyroid cancer	Mike Rothenberg ( <i>LOXO Pharm</i> )

11:25-11:45 PM	Single-agent, precision medicine engineered to simultaneously target RET, RET mutants, and tumor stroma	Brendan Frett ( <i>Syntactix Pharm</i> )
11:45 - 12:15 PM	Therapeutic opportunities arising from genomic analysis of poorly differentiated and anaplastic thyroid cancer.	Jim Fagin
12:15-12:30 PM	Discussion and questions	
<b>12:30–1:30 PM</b>	<b>Lunch (working lunch – business meeting)</b>	Lori & Dwight <i>Dave Pfister – Protocol Cmte reorganization</i>
<b>1:30 PM– 4:00 PM</b>	<b>Session III –Microenvironment</b>	
1:30-2:00 PM	Exosomes and metastases	Matt Ringel
2:00-2:30 PM	Physiologic-induction of tissue remodeling Promotes Breast Cancer Metastasis in Young Women	Pepper Schedin
2:30-3:00 PM	Genetic evolution of cancer	James DeGregori
<b>3:00-3:15 PM</b>	<b>Break</b>	
3:15 – 3:45 PM	Drug development and an update on the Center for Personalized Cancer Therapeutics.	Ross Cagan
3:45-4:00 PM	<i>ITOG trials update:</i> Targeted Therapies plus RAI Trials	Alan Ho
<b>4:30 PM</b>	<b>Depart for Red Rocks</b>	
<b>5:15-6:00 PM</b>	<b>Explore Red Rocks (group photo)</b>	
<b>6:15-10:00 PM</b>	<b>Dinner</b> "Cardiac Care in Colorado in the 1950s and How it Affected a President" <i>Peter Buttrick, MD, Head, Division of Cardiology, Senior Associate Dean for Academic Affairs University of Colorado School of Medicine</i>	<i>The Fort, Morrison, CO</i>  The Robert F. Gagel Discovery Award Rick Abrams Memorial Lecture
<b>Monday, May 2</b>		
<b>6:45-7:30 AM</b>	<b>Breakfast</b>	

<b>7:30-9:00 AM</b>	<b>Session IV – Preclinical models and Clinical Trial Development</b>	
7:30-7:45 AM	Robert F Gagel Discovery Award Presentation	TBD
7:45-8:15 AM	Targeting gene fusions in cancer	Robert Doebele
8:15-8:45 AM	Overcoming kinase inhibitor resistance	Rebecca Schweppe
8:45-9:15 AM	Advanced humanized models of cancer	Antonio Jimeno
9:15-9:45 AM	Biomarker-driven trials in colorectal cancer	Wells Messersmith
9:45-10:15 AM	Highs and lows of precision oncology in lung cancer	Ross Camidge
<b>10:15-11:00 AM</b>	<b>Break and Tour of the Eisenhower Suite (Western White House)</b>	
<b>11:00 – 12:30 PM</b>	<b>Session V – Clinical Trials</b>	
11:00-11:15 AM	Navigating the Priorities and Principles of the NCI HNSC	Ezra Cohen
11:15 -11:30 AM	Opportunities and Challenges with Being a PI on an ITOG Trial	Manisha Shah and Nathan Foster
11:30-11:45 AM	THYCAT Adaptive Platform Trials	Jai Balkissoon
11:45-12:00 noon	Clinical trials discussion	
<b>12:00 – 1:00 PM</b>	<b>Session VI – Clinical Trials</b>	
<b>12:00-1:00 PM</b>	<b>Working Lunch</b>	
12:30-12:45 PM	<i>ITOG trials update:</i> Lenvatinib in ATC	Lori Wirth
12:45-1:00 PM	RAIR DTC patients: Radium 223 therapy for bone metastases	Sophie Leboulleux
1:00-1:15 PM	Combination therapy trials at MSKCC	Eric Sherman
1:15-1:30 PM	Clinical trials discussion	